July issue of Health Affairs examining PEPFAR impact to be discussed at briefing on Tuesday

NewsGuard 100/100 Score

The July 2012 issue of Health Affairs, published Monday, examines the impact of PEPFAR, focusing on "the origins of the program; the lessons learned from implementation; the successes achieved in terms of human health and well-being; and the opportunities that now exist to lay the groundwork for an 'AIDS-free generation,'" the Health Affairs Blog reports, noting, "The new Health Affairs issue will be discussed [Tuesday] morning at a Washington, D.C., briefing" (Fleming, 7/10). U.S. Global AIDS Coordinator Ambassador Eric Goosby will deliver keynote remarks at the briefing, a U.S. Department of State press notice reports (7/9). In a paper to be discussed at the event, Kartik Venkatesh, an M.D./Ph.D. graduate student at Brown University, writes that PEPFAR's adoption of generic drug usage made the program "a success," a Brown University press release notes (7/9). In another study assessing the effects of PEPFAR-supported HIV programs, researchers at Columbia University's Mailman School of Public Health found "PEPFAR-funded, HIV-related projects were linked to more deliveries in health facilities," according to a Columbia University press release (7/9). 


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidates show promise to reverse HIV immune evasion